Randomized study comparing six times of epirubicin instillation for 2.5 months with six times for two weeks in superficial bladder cancer after transurethral resection of bladder tumor

Randomized study comparing six times of epirubicin instillation for 2.5 months with six times for two weeks in superficial bladder cancer after transurethral resection of bladder tumor - Randomized study comparing six times of epirubicin instillation for 2.5 months with six times for two weeks in superficial bladder cancer after transurethral resection of bladder tumor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000257

Enrollment

300

Registered

2005-09-30

Start date

2002-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Superficial bladder cancer

Interventions

40mg Epirubicin / 40ml sailine weekly instillation for two weeks, then bi-weekly instillation for 8weeks 40mg Epirubicin / 40ml sailine three daily instillation a week for two weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically confirmed superficial trancitional cell carcinoma of the bladder (Ta or T1, G1 or G2) After TURBT Primary and multiple tumor or recurrent tumor Written informed consented

Exclusion criteria

Exclusion criteria: Synchronous CIS G3 tumor Severe complication History of allergy for Epirubicin Active infection Active synchronous malignancy History of upper urinary tract malignancies

Design outcomes

Primary

Measure	Time frame
Recurrence	—

Countries

Japan

Contacts

Public ContactHideyuki Akaza MD

University of Tsukuba Department of Urology

029-853-3223

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026